Studie von [177LU] Lu-dotatat bei Erwachsenen mit progressiver intrakranieller Grad 1-3 Meningiom (MOMENTUM-1)
Momentum-1: Eine multizentrische, randomisierte, offene Label-Phase-II-Studie von [177LU] Lu-Dotatat bei Erwachsenen mit progressiver intrakranieller Grad 1-3 Meningiom
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Study participants will be randomized by a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the [177Lu]Lu-DOTATATE alternative treatment arm.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Sylvia C Kurz, MD,PhD
- Telefonnummer: 203-785-5616
- E-Mail: Sylvia.Kurz@yale.edu
Studienorte
-
-
California
-
Irvine, California, Vereinigte Staaten, 92697
- Rekrutierung
- University of California, Irvine
-
Hauptermittler:
- Daniela Bota, MD, PhD
-
Kontakt:
- Manisha Dandekar
- E-Mail: mdandeka@hs.uci.edu
-
La Jolla, California, Vereinigte Staaten, 92093
- Rekrutierung
- University of California San Diego - Moores Cancer Center
-
Hauptermittler:
- Jona Hattangadi-Gluth, MD
-
Kontakt:
- Mohammad Amjad
- E-Mail: mtamjad@health.ucsd.edu
-
Los Angeles, California, Vereinigte Staaten, 90033
- Rekrutierung
- USC Keck School of Medicine
-
Kontakt:
- Christine Duran
- E-Mail: duran_c@med.usc.edu
-
Hauptermittler:
- Aram Modrek, MD, PhD
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Rekrutierung
- Yale University
-
Hauptermittler:
- Sylvia Kurz, MD, PhD
-
Kontakt:
- Amy Rodrigues, CCRC
- Telefonnummer: 203-260-9632
- E-Mail: amy.rodrigues@yale.edu
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Rekrutierung
- Baptist MD Anderson Cancer Center
-
Hauptermittler:
- Michael Olson, MD PhD
-
Kontakt:
- E-Mail: CTOinterest@bmcjax.com
-
Unterermittler:
- Andre Alvarez, MD PhD
-
Miami, Florida, Vereinigte Staaten, 33146
- Rekrutierung
- University of Miami
-
Kontakt:
- Lily Friedman
- E-Mail: lxf699@med.miami.edu
-
Hauptermittler:
- Marina Kushnirsky, MD
-
Miami, Florida, Vereinigte Staaten, 33176
- Rekrutierung
- Baptist Health Medical Group Oncology
-
Hauptermittler:
- Matthew Hall, MD
-
Kontakt:
- Nicolas Morales
- E-Mail: nicolas.morales1@baptisthealth.net
-
Tampa, Florida, Vereinigte Staaten, 33543
- Rekrutierung
- Moffitt Cancer Center
-
Kontakt:
- Abdullah Abdelkawy
- E-Mail: Abdullah.abdelkawy@Moffitt.org
-
Hauptermittler:
- Andre Luiz Beer Furlan, MD, PhD
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30318
- Rekrutierung
- Piedmont Healthcare
-
Kontakt:
- Jeff Whorton, BSN,RN
- E-Mail: jeff.whorton@piedmont.org
-
Hauptermittler:
- Adam Nowlan, MD, MPH
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Rekrutierung
- Indiana University
-
Hauptermittler:
- Kathryn Nevel, MD
-
Kontakt:
- Lauren Perrey-Moore, RN
- E-Mail: lperry@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa Health Care
-
Kontakt:
- Kristin West, RN, BSN
- E-Mail: kristin-gaimari-varner@uiowa.edu
-
Hauptermittler:
- Kristin Plichta, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana-Farber/Harvard Cancer Center
-
Kontakt:
- Kathryn Partridge
- E-Mail: Kathryn_Partridge@DFCI.HARVARD.EDU
-
Hauptermittler:
- Gilbert Youssef, MD
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan Rogel Cancer Center
-
Kontakt:
- Jen Thomas
- E-Mail: jennifkt@med.umich.edu
-
Hauptermittler:
- Sean Miller, MD
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Rekrutierung
- Henry Ford Hospital
-
Kontakt:
- Jennifer Cooper
- E-Mail: jcoope13@hfhs.org
-
Hauptermittler:
- Tobias Walber, MD, PhD, MPH
-
-
New York
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- NYU Lagone Health
-
Hauptermittler:
- Marissa Barbaro, MD
-
Kontakt:
- Olga Garduno-Ortega
- E-Mail: Olga.Garduno-Ortega@nyulagone.org
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 22708
- Rekrutierung
- Duke University Medical Center
-
Hauptermittler:
- Margaret Johnson, MD
-
Kontakt:
- Kelly Moulton
- E-Mail: kelly.moulton@duke.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Thomas Jefferson University Hospital
-
Hauptermittler:
- Iyad Alnahhas, MD
-
Kontakt:
- Oleksandr Kolesnikov
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- MD Anderson Cancer Center
-
Kontakt:
- Wathoo Chetna
- E-Mail: cwathoo@mdanderson.org
-
Hauptermittler:
- Carlos Kamiya-Matsuoka, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Medical College of Wisconsin
-
Kontakt:
- Bailee Fritz
- E-Mail: bfritz@mcw.edu
-
Hauptermittler:
- Michael Straza, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
STEP 1 REGISTRATION
- Aged >= 18 years
- Histologically confirmed diagnosis of WHO grade 1-3 meningioma
- Disease progression following at least one prior surgical intervention (biopsy or resection) and at least one prior course of radiation.
- The patient is not considered a candidate for additional surgery and/or radiation or the patient has declined additional surgery and/or radiation.
- Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
- Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion
- The following scans must be available for submission for central radiology review:
- Pre-progression gadolinium-enhanced MRI brain scan no older than 12 months (379 days) that serves as a reference for evaluation of radiographic disease progression
- Progression gadolinium-enhanced MRI brain scan
STEP 2 REGISTRATION
- Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion.
- [68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
- Both the patient and investigator must agree that the patient will NOT receive SSTR2-targeted therapy, surgical resection, or radiation therapy until progression of disease while on study treatment.
- Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
- Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
- Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):
- Absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin ≥ 8 g/dL
- Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
- AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN)
- Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
- Potassium within normal limits.
Exclusion Criteria:
- Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
- Patients with radiation-associated meningiomas.
- Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column. Meningiomas invading the skull base or orbits are not excluded.
- Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide. No limit on number of prior non-SSTR2-tartgeted systemic therapies.
- Unstable neurological symptoms requiring steroids to control symptoms at a dose of >2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
- Patients requiring immediate local therapy (e.g. surgical resection).
- Surgical procedure within the timeframes listed below, prior to step 2 registration.
- 28 days from any prior craniotomy
- 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
- Treatment within the timeframes specified below, prior to step 2 registration.
- 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
- 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
- A target lesion is excluded if it has received any of the following:
- More than 2 total prior courses of radiation
- More than 1 prior course of standard fractionated external beam radiation therapy (EBRT)
- Radiation treatment to the target lesion completed <24 weeks (168 days) before Step 2 registration.
For purposes of this criterion, one course of EBRT counts as one course regardless of duration, and each course of stereotactic radiation (1-5 fractions) counts as one course. Accordingly, a target lesion may have received at most one prior course of EBRT plus one prior course of stereotactic radiation, or two prior courses of stereotactic radiation. Prior radiation history must be evaluated on a lesion-by-lesion basis, including radiation delivered before any subsequent surgical resection.
- All types of radioligand therapy at any time prior to registration. Radioligands received for diagnostic purposes are not exclusionary.
- Known hypersensitivity to somatostatin analogues or any component of the [68Ga]Ga- DOTATATE or [177Lu]Lu-DOTATATE formulations.
- Active infection requiring current use of intravenous therapy with antibiotics.
- Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
- An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
- Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: [177Lu]Lu-DOTATATE
Study participants receive [177Lu]Lu-DOTATATE |
The treatment regimen consists of 4 (+2 optional) administrations of [177Lu]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
Andere Namen:
|
|
Sonstiges: Control
Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to [177Lu]Lu-DOTATATE at progression |
Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Systemic SOC therapy with one of the following agents: bevacizumab, everolimus, or sunitinib.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression Free Survival (PFS)
Zeitfenster: Assessed up to 4 years
|
Proportion of patients alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression free survival at 6 months (PFS-6)
Zeitfenster: 6 months
|
Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria |
6 months
|
|
Overall Survival at 12 months (OS-12)
Zeitfenster: 12 months
|
Proportion of participants alive at 12 months |
12 months
|
|
Overall survival (OS)
Zeitfenster: Assessed up to 4 years
|
Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
|
Progression-free Survival after cross-over (PFS2)
Zeitfenster: Assessed up to 4 years
|
Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first. |
Assessed up to 4 years
|
|
Disease Control Rate (DCR)
Zeitfenster: Assessed up to 4 years
|
Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria |
Assessed up to 4 years
|
|
Objective response rate (ORR)
Zeitfenster: Assessed up to 4 years
|
Proportion of patients achieving complete or partial response as per RANO meningioma criteria. |
Assessed up to 4 years
|
|
Number of participants by highest grade treatment-emergent adverse event (TEAE):
Zeitfenster: Assessed up to 4 years
|
Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event). |
Assessed up to 4 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Sylvia C Kurz, MD, PhD, Yale University
- Hauptermittler: Erik P Sulman, MD,PhD, Duke University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Neubildungen nach Standort
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Nervengewebe
- Neubildungen des Nervensystems
- Neubildungen, Gefäßgewebe
- Meningeale Neubildungen
- Neubildungen des zentralen Nervensystems
- Meningiom
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Azolen
- Indolen
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Makroliden
- Laktone
- Pyrrolen
- Sirolimus
- Sunitinib
- Bevacizumab
- Everolimus
- Lutetium lu 177 Dotatat
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- RTOG 3523
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .